Management of Patients with Cerebellar Ataxia During the COVID-19 Pandemic: Current Concerns and Future Implications.


Journal

Cerebellum (London, England)
ISSN: 1473-4230
Titre abrégé: Cerebellum
Pays: United States
ID NLM: 101089443

Informations de publication

Date de publication:
Aug 2020
Historique:
pubmed: 15 5 2020
medline: 17 7 2020
entrez: 15 5 2020
Statut: ppublish

Résumé

The current worldwide severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that causes coronavirus disease 2019 (COVID-19) has brought some medical systems to the brink of collapse. This crisis is also negatively impacting the care of patients with non-COVID-19 conditions, including those with cerebellar ataxia (CA). Older patients with CA and those with immune-mediated ataxias on immunosuppressive medication are potentially at high risk of developing serious complications of the infection, although it is also possible that immunosuppressive agents may provide a defense against cytokine storm. This has implications for even greater attention to preventing contracting the disease through physical distancing and/or isolation. The CA patient population is also at higher risk because of the neurological complexities of their underlying disorder and the comorbid medical illnesses that often accompany the genetic ataxias. As the disruption of social patterns and healthcare delivery in response to the crisis continues, interruption of rehabilitation, speech and language therapy, and face-to-face consultations threatens to have a negative impact on the course and well-being of CA patients. Mental and physical health is also potentially at greater risk because the prevailing uncertainty and anxiety may be superimposed upon cerebellum-specific neuropsychological challenges. We identify and review some of the short- and long-term consequences of this global pandemic for the community of ataxia patients and their families and for the clinical and academic neurologists/ataxiologists caring for these patients. This includes the recognition that telemedicine has emerged as a principle means of caregiver-patient contact and that neurological manifestations of COVID-19 including those specific to cerebellar neurobiology are increasingly recognized and will require close surveillance and monitoring. This COVID-19 Cerebellum Task Force consensus provides some guidance on how we may approach this uncertain time and consider preparing for the new realities we face in CA patient care once this acute crisis has passed.

Identifiants

pubmed: 32405955
doi: 10.1007/s12311-020-01139-1
pii: 10.1007/s12311-020-01139-1
pmc: PMC7220536
doi:

Types de publication

Journal Article Practice Guideline Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

562-568

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Références

J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235486
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Mov Disord. 2010 Oct 15;25(13):2239-46
pubmed: 20737551
Ecancermedicalscience. 2020 Mar 27;14:1022
pubmed: 32256705
Psychiatry Res. 2020 Feb 28;286:112903
pubmed: 32146245
J Neurol Sci. 2020 May 15;412:116803
pubmed: 32247193
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
J Neurol. 2013 Dec;260(12):3134-43
pubmed: 24122064
Brain. 1998 Apr;121 ( Pt 4):561-79
pubmed: 9577385
Cerebellum Ataxias. 2015 Feb 27;2:2
pubmed: 26331045
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Eur J Neurol. 2020 Sep;27(9):1764-1773
pubmed: 32333487
J Infect. 2020 Jun;80(6):e14-e18
pubmed: 32171866
J Biol Regul Homeost Agents. 2020 Apr 07;34(2):339-343
pubmed: 32253888

Auteurs

Mario Manto (M)

Unité des Ataxies Cérébelleuses, Service de Neurologie, CHU-Charleroi, 6000, Charleroi, Belgium. mmanto@ulb.ac.be.
CHU-Charleroi and Service des Neurosciences, University of Mons, 7000, Mons, Belgium. mmanto@ulb.ac.be.

Nicolas Dupre (N)

Department of Medicine, Faculty of Medicine, Université Laval & Neuroscience Axis, CHU de Québec-Université Laval, Quebec City, QC, Canada.

Marios Hadjivassiliou (M)

Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.

Elan D Louis (ED)

Department of Neurology and Neurotherapeutics, University of Texas Southwestern, Dallas, TX, USA.

Hiroshi Mitoma (H)

Department of Medical Education, Tokyo Medical University, Tokyo, Japan.

Marco Molinari (M)

IRCCS Fondazione S. Lucia, Rome, Italy.

Aasef G Shaikh (AG)

Department of Neurology, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland VA Medical Center, Cleveland, OH, USA.

Bing-Wen Soong (BW)

Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.
Department of Neurology, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan.
Department of Neurology, Taipei Veterans General Hospital, and Brain Research Center, National Yang-Ming University, Taipei, Taiwan.

Michael Strupp (M)

Department of Neurology, Ludwig Maximilians University, Munich, Germany.

Frank Van Overwalle (F)

Brain, Body and Cognition Lab, Faculty of Psychology, Vrije Universiteit Brussel, Brussels, Belgium.

Jeremy D Schmahmann (JD)

Ataxia Center, Cognitive Behavioral Neurology Unit, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH